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Background: Recently, a number of studies using intra-articular application of tranexamic acid (IA-TXA), with
different dosage and techniques, successfully reduced postoperative blood loss in total knee replacement (TKR).
However, best of our knowledge, the very low dose of IA-TXA with drain clamping technique in conventional TKR
has not been yet studied. This study aimed to evaluate the effectiveness and dose-response effect of two low-dose
IA-TXA regimens in conventional TKR on blood loss and blood transfusion reduction.
Methods: Between 2010 and 2011, a triple-blinded randomized controlled study was conducted in 135 patients
undergoing conventional TKR. The patients were allocated into three groups according to intra-articular solution
received: Control group (physiologic saline), TXA-250 group (TXA 250 mg), and TXA-500 group (TXA 500 mg). The
solution was injected after wound closure followed by drain clamping for 2 hours. Blood loss and transfusion were
recorded. Duplex ultrasound was performed. Functional outcome and complication were followed for one year.
Results: There were forty-five patients per groups. The mean total hemoglobin loss was 2.9 g/dL in control group
compared with 2.2 g/dL in both TXA groups (p > 0.001). Ten patients (22%, control), six patients (13%, TXA-250) and
none (TXA-500) required transfusion (p = 0.005). Thromboembolic events were detected in 7 patients (4 controls, 1
TXA-250, and 2 TXA-500). Functional outcome was non-significant difference between groups.
Conclusions: Combined low-dose IA-TXA, as 500 mg, with 2-hour clamp drain is effective for reducing postoperative
blood loss and transfusion in conventional TKR without significant difference in postoperative knee function or
complication.
Trial registration: ClinicalTrials.gov NCT01850394.
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Extensive perioperative blood loss (PBL) requiring blood
transfusion is one of the most important factors concern-
ing by many surgical specialists due to risk of bleeding-
related complication and transfusion-related morbidity
[1,2]. Among the orthopedic interventions, total knee
replacement (TKR) is a major surgery associated with
considerable amount of blood loss, and therefore, result-
ing in a significant number of patients needed transfusion* Correspondence: viroj.k2009@yahoo.com
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distribution, and reproduction in any mediumrequirement. Regarding of the proven methods used for re-
ducing PBL in TKR, tranexamic acid (TXA), an anti-
fibrinolytic agent, has been demonstrated ability to decrease
PBL and proportion of patients required postoperative
blood transfusion and could be applied via either intraven-
ous application [3] or intra-articular injection [4]. However,
the intravenous application of TXA has a major disadvan-
tage on uncertain risk of drug-induced venous thrombo-
embolic (VTE) complication from prolonged high systemic
drug level especially with multiple injection or continuous
infusion regimens [5]. Thus, for safety concern of the VTE
complication, there has been a growing attention of using
TXA as intra-articular agent (IA-TXA) in TKR [4,6-12].ed Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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application to reduce postoperative blood loss and knee
swelling in conventional TKR (Con-TKR); however, there
still has been no guideline for using of IA-TXA such as
the dosage of TXA which varied from 500 mg to 3,000
mg, using of drain, time interval of drain clamping, and
the use of concomitant carbazochrome sodium sulfate
mixed into the intra-articular solution [6-8,10-13]. More-
over, the absorption of TXA into blood had been shown
to be above therapeutic concentration [12]. Recently
Sa-ngasoongsong et al., developed a new IA-TXA method,
combined low dose of TXA (as 250 mg) with 2-hour
clamp drain, for reducing blood loss and transfusion
in computer-assisted surgery total knee replacement
(CAS-TKR) without any significant complication [9]. This
technique should also be able to use in conventional TKR
that carries risk of higher blood loss.
The objective of this study included the following: (1)
whether low dosage IA-TXA solution was able to reduce
PBL and need of blood transfusion in conventional TKR
and if it can then, (2) how the efficacy of IA-TXA does
depend on the dosage of TXA used?
Methods
This was a single-centered, prospective triple-blinded
randomized study with 1:1:1 allocation ratio and was ap-
proved by Committee on Human Right Related to Re-
searches Involving Human Subjects (Protocol number
ID 01-53-06). Informed consent was obtained from all
patients who participated in this study, before the sur-
gery was scheduled, in accordance with the Declaration
of Helsinki. The manuscript was prepared according to
the Consolidated Standards of Reporting Trials (CON-
SORT) 2010 guideline [14].
The inclusion criterion was the patients diagnosed as
primary knee osteoarthritis and underwent unilateral
primary cemented Con-TKR between January 2010 and
January 2011. The exclusion criteria were (1) no risk of ab-
normal bleeding tendency or bleeding disorder (normal
coagulogram, serum creatinine < 2.0 mg/dL, stop nonste-
roidal anti-inflammatory drugs and antiplatelet drugs
more than 7 days; and (2) no contra-indication for TXA
use (no active intravascular clotting process, no acquired
defective colour vision, no subarachnoid hemorrhage, no
hypersensitivity to TXA, and no any of history of serious
adverse effects, thrombotic disorder and hematuria).
The blocked-randomization was generated by STATA
11.0 software (Stata Corp, College Station, Texas, USA),
with block size of nine, and further concealed with sealed
envelopes in the sequentially numbered container. After
fascia closure, one of our authors (Su.W.), who did not in-
volve in the operation and in outcome assessment, was re-
sponsible for opening these envelopes and preparing the
study medication. Then all patients were allocated to oneof three groups; control group, TXA-250 group or TXA-
500 group (Figure 1).
All of the solution in this study was prepared as total
25-ml volume in the same-size syringe, according to allo-
cation received, under sterile condition and behind the
fluoroscopic scene in order to blind surgeon and outcome
assessor. Due to a fixed concentration of TXA medication
(250 mg per 5 ml, Transmin®, OLIC (Thailand) Limited,
Ayutthaya, Thailand), the dosage of TXA could be calcu-
lated from the volume of TXA used. In TXA-250 and
TXA-500 group, the solution contained 250-mg (5 ml) or
500-mg (10 ml) of TXA respectively, and then were added
with physiologic saline to create a total volume of 25 ml.
In the control group, the solution was 25 ml of physiologic
saline. All of prepared solution had the same appearance.
This solution was injected to the knee joint via drain tube
after fascia closure, in order to prevent leakage. Then
the vacuum drain was connected to the drain tube and
clamped for 2 hours.
Demographic data such as age, gender, height, weight,
underlying disease, side of operation, American Society of
Anesthesiologists (ASA) physical status [15], preoperative
hemoglobin (Hb) and hematocrit (Hct) were collected
preoperatively, by research assistant, and then further cal-
culated into body mass index (BMI) and estimated blood
volume (EBV) [16]. Preoperative mechanical axis and
baseline knee function score, as Knee Society Knee score
(KSK) and Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) were obtained [17,18].
The surgery was performed by one of the authors (V.K.),
who was an experienced arthroplasty surgeon. The decision
on anesthetic technique, general or regional anesthesia,
depended on the anesthesiologists who did not involve in
the study. The prostheses used in this present study were
Nexgen® total knee system (Zimmer Inc, Warsaw, Indiana,
USA). Due to awareness of sex-related difference in antero-
posterior diameter of the distal femur, Nexgen® Gender
prosthesis was specifically used in female patient while
Nexgen® Flex prosthesis was used in male patient. The
pneumatic tourniquet was applied at proximal thigh with
pressure as 350 mmHg. The surgical approach was midline
skin incision, medial parapatellar arthrotomy and midvas-
tus incision. After the bony structure was prepared, all
prosthesis components were inserted with full cementation
(Palacos®, Hevaeus Medical GmbH, Germany). A standard
drain tube (size 8 Redon drain, B-Braun Ltd.) was placed
deep into knee joint, exited superolaterally, and connected
to high pressure vacuum drain (Drainobag® 600V Lock,
B-Braun, Melsungen AG, Germany). No superficial drain
was used in this study. After fascia closure, one of our au-
thors (Su.W.), was assigned to open the sealed envelopes
and prepare the solution in 25-ml syringe behind the scene
under sterile technique in order to blind the surgeon. Then
the prepared sterile solution, either placebo or TXA
Figure 1 Illustration showed the flow diagram of this study.
Figure 2 The mean accumulated drainage volume (ADV) at
each time point throughout 48-hour drainage recorded period,
in all three groups, demonstrated a significant reduction in
both TXA groups only the early period after clamp release (the
first 12-hour period in TXA-250 group and the first 20-hour
period in TXA-500 group) (★ = p < 0.05).
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knee joint. Subcutaneous and skin closure was performed
subsequently. Bulky compressive dressing was applied and
the drain was clamped before tourniquet was deflated. The
2-hour period of drain clamping and the time of drain
opening were then written on the drain bottle and further
informed to the well-trained research assistant, who was
blinded to group allocation. At the ward, the research as-
sistant was responsible for fully opening the drain at the
setting time and recording the amount of drain volume as
data collection protocol.
Basic postoperative data, such as drainage volume,
Hct, Hb, amount of blood transfusion, and WOMAC
score, were collected by a well-trained research assistant
who was blinded to the group allocation and did not in-
volve in the medication preparation process. Postopera-
tive data requiring clinical examination or physician
diagnosis, such as range of motion, and diagnosis of
complication, were collected by one of the authors. Both
of them were blinded to the treatment allocation. Accu-
mulated drain volume (ADV) was recorded by research
assistant at 1, 2, 4, 6, 8, 10, 12, 16, 20, 24, 36, and 48
hours after clamp release (Figure 2). Drain re-clamp
protocol was used to prevent severe immediate brisk
blood loss by re-clamping the drain, for 30 minutes, if
drainage blood loss after release was more than 250 ml/
hour in the first hour and then recorded as incidence of
re-clamping. If the wound had excessive bleeding de-
tected by bloody oozing on compressive dressing, the
dressing was changed and recorded as incidence of re-
dressing. These re-clamping and re-dressing events were
managed and recorded by the research assistant who did
not know the allocation result. Postoperative Hct was
measured immediately at ward and subsequently at thefourth hour, then every 8 hours on the first day, every 12
hours on the second day and once daily until the fourth
postoperative day. If Hct level was less than 25%, Hb
was measured in order to evaluate the need of transfu-
sion. According to ASA guideline, blood transfusion was
considered when Hb was less than 8 gm% or the patient
had positive anemic symptom (dyspnea, tachypnea and
hypoxemia) [19]. On the fourth postoperative day, Hb
was measured in order to calculate for total blood loss.
Postoperative blood loss was measured in three differ-
ent methods same as our previous study [9]: drainage
blood loss (DBL), total Hb loss (THL) and calculated
total blood loss (CTBL). THL and CTBL were calculated
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increment per hour was further calculated, as drainage
blood loss rate (DBLR), by dividing DBL increment in
each time interval with number of hours in that time
interval [9].
Blood transfusion requirement was measured by re-
cording the number of patients receiving transfusion
and amount of blood transfusion in unit.
The patients were all sent to document deep vein
thrombosis (DVT) by duplex ultrasound, performed by a
senior radiologist (B.W.), on the fourth postoperative day.
If the patients developed postoperative clinical presenta-
tion suspected pulmonary embolism (PE) such as acute
dyspnea or unexplained hypoxemia, the computer tomo-
graphic angiogram was then performed to confirm the
diagnosis by the same senior radiologist. The incidence of
DVT and PE was recorded as VTE complication.
Functional outcomes, such as KSK and WOMAC score,
were evaluated at the clinic at 3-month, 6-month and
1-year period postoperatively.
Postoperative complications such as wound hematoma,
surgical site infection or systemic infection were evaluated
at ward, at clinic as time of follow-up and/or by phone
interview periodically.
Statistical analysis was performed using Stata software
version 11.0 (Stata Corp, College Station, Texas, USA).
Intention-to-treat analysis was applied. Normality of data
was tested by Kolmogorov-Smirnov test. Continuous data
were presented as mean and standard deviation, and com-
pared with one-way analysis of variance (ANOVA). The
comparison of drainage blood loss parameters between
groups according to time was performed by repeated
measurement with Scheffe test post hoc analysis. Categor-
ical data were presented as proportion and compared with
Chi-square test. Significant difference was considered if
p value < 0.05.
Sample size estimation was calculated by using data re-
view on hemoglobin loss in our patients who underwent
primary Con-TKR before this study (mean hemoglobin
loss ± standard deviation = 3.3 ± 1.0 g/dl). We assumed
that this IA-TXA application should reduce blood loss
more than 20% compared with control group. Setting the
pre-study power of test (β) as 0.8, significant difference (α)
as 0.05, and the ratio of sample size in each group as 1:1:1;
therefore, the sample size of each group was 45 patients.
Results
From January 2009 to January 2010, there were 152 pa-
tients that underwent primary unilateral Con-TKR partici-
pated into this study. Seventeen patients were excluded
that including refusal to participate (4 patients), serum
creatinine more than 2.0 mg% (4 patients), rheumatoid
arthritis (4 patients), abnormal coagulogram (3 patients),
and history of stroke (2 patients). A total of 135 patientswas recruited and then equally randomized into each
group (45 patients per group). All patients had completed
1-year follow-up examination (Figure 1). Demographic
data were shown in Table 1. There was no significant dif-
ference between all three groups in terms of age, sex, BMI,
EBV, number of diabetes patients, ASA physical status,
side of operation, preoperative mechanical axis, preopera-
tive functional score, anesthetic technique, operative time,
and incision size. However, TXA-500 group showed sig-
nificantly higher in preoperative Hb level compared with
TXA-250 group (p = 0.02).
The mean THL and CTBL in TXA-500 and TXA-250
groups were significantly lower compared to control
group (p <0.001 both). However, the mean DBL in both
TXA groups were non-significantly lower than control
group (p = 0.09). Allogeneic blood transfusion in TXA-
500 group (none) was also significantly lower than TXA-
250 group (six patients) and control group (ten patients)
(p = 0.005) (Table 2).
The effects of two TXA regimens on blood loss reduc-
tion were demonstrated in Figures 2 and 3. TXA-500
group had the greatest reduction in the mean ADV at
every time point and these values were significantly lower
than control group (p <0.05), from the first hour to the
twentieth hour after clamp release. TXA-250 group
showed significantly lower in the mean ADV (p <0.05)
than control group only from the first hour to the twelfth
hour after clamp release (Figure 2). TXA-500 group also
had the greatest and significant reduction (p <0.05) in the
mean DBLR compared to control group during the first 4-
hour period after clamp release, while those in TXA-250
group were significantly lower (p <0.05) than control
group only for the first 2-hour period after clamp release
(Figure 3).
WOMAC and KSK scores were significantly improved
postoperatively in all three groups throughout 1-year
follow-up period (p <0.001 both), and no significant
difference between groups was detected in both scores
(p = 0.42 and 0.91, respectively). The incidence of re-
clamping and re-dressing in TXA-500 group were sig-
nificantly lower than other two groups (p =0.01, 0.05
respectively). There was no significant difference in VTE
complications (1 symptomatic PE and 3 DVT in control
group, 1 DVT in TXA-250 group, and 2 DVT in TXA-
500 group, p = 0.35). None of postoperative infection
was detected in this study (Table 3).
Furthermore, there was an unexpected finding in this
study. While the mean DBLR in control group, after the
first 4-hour period, was descended in an exponentially
fashion, those in both TXA groups were decreased at a
slower rate. Consequently, a significant increase of the
mean DBLR in both TXA groups, compared to control
group, was demonstrated in a period between 8 and 20
hours (p < 0.05) (Figure 3).
Table 1 The patients’ preoperative characteristics data
Control group TXA-250 group TXA-500 group p-value
(n = 45) (n = 45) (n = 45)
Demographic characteristics
Age✝ (year) 66.2 (7.3) 67.6 (8.7) 68.1 (6.2) 0.44
Female gender◆ 43 (95.6%) 42 (93.3%) 40 (88.9%) 0.47
Body mass index✝ (kg/m2) 26.3 (3.7) 26.2 (3.7) 27.3 (4.7) 0.37
Estimated blood volume✝ (ml) 3146 (310) 3090 (246) 3227 (401) 0.14
DM◆ 34 (75.6%) 36 (80.0%) 34 (75.6%) 0.9
ASA classification (II/III) (no. of
patients)
29/16 20/25 20/25 0.1
Preoperative laboratory values
Preoperative hemoglobin✝ (g/dL) 12.1 (1.1) 11.9 (1.0) 12.6 (1.3)*c 0.02*
Surgical characteristics
Regional anesthesia◆ 42 (93%) 39 (87%) 43 (96%) 0.38
Right side◆ 26 (57.8) 25 (55.6) 23 (51.1) 0.86
Preoperative mechanical axis◼ 4.9 varus (15 varus to 8
valgus)
5.0 varus (16 varus to 13
valgus)
5.2 varus (20 varus to 6
valgus)
0.97
Operative time✝ (minute) 79.1 (14.3) 78.8 (13.0) 81.1 (13.1) 0.65
Surgical incision✝ (cm) 12.5 (2.2) 12.3 (2.2) 13.2 (1.2 ) 0.09
Functional characteristics
Preoperative KSK Score✝ 77.3 (11.0) 76.8 (11.9) 76.4 (13.3) 0.94
Preoperative WOMAC score✝ 59.8 (9.5) 60.3 (9.8) 60.0 (9.7) 0.98
✝ = The values were presented as mean (standard deviation), ◼ = The values were presented as mean (range).
◆ = The values were presented as number of patients having that condition (percentage of this group).
TXA; tranexamic acid, DM; patient having underlying diabetes mellitus, ASA; American Society of Anesthesiologists.
KSK; Knee Society Knee, WOMAC; Western Ontario and McMaster Universities Osteoarthritis Index.
* = p <0.05; c = comparison between TXA-250 and TXA-500 group with p < 0.05.
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Recently, intra-articular tranexamic acid (IA-TXA) applica-
tion has become one of most popular methods for reducing
blood loss and transfusion requirement in conventional
TKR (Con-TKR) [6-12]. However, to our knowledge, previ-
ous studies demonstrated ability to reduce postoperative
blood loss with a variety of techniques and mostly using
high dosage of tranexamic acid (TXA) (500-3,000 mg)
[6,7,10-12], while our previous study also showed benefit ofTable 2 Blood loos and blood transfusion outcome in all thre
Control group
(n = 45)
Blood loss outcome variables
Drainage blood loss✝ (ml) 546.9 (273.0)
Total hemoglobin loss✝ (g/dl) 2.9 (1.2)
Calculated total blood loss✝ (ml) 329.2 (119.4)
Packed red blood-cell transfusion
Blood transfusion use◆ 10 (22%)
✝ = The values were presented as mean (standard deviation); *, p < 0.05; **, p < 0.00
◆ = The values were presented as number of patients having that condition (percen
a = comparison between control and TXA-250 group with p < 0.05.
b = comparison between control and TXA-500 group with p < 0.05.blood loss and transfusion reduction in computer-assisted
surgery TKR with combined low-dose TXA (250 mg) with
2-hour clamp drain [9]. In this prospective randomized
controlled study, we aimed to evaluate the efficacy of two
regimens of low-dose IA-TXA (250 mg and 500 mg) com-
bined with 2-hour clamp drain, and the effect of the differ-
ent dosage on the reduction of blood loss and transfusion.
This present study had some limitations. First, although
our result showed an ability to decrease blood loss ande groups
TXA 250 mg TXA 500 mg p-value
(n = 45) (n = 45)
475.0 (254.4) 430.2 (224.0) 0.09
2.2 (0.7)**a 2.2 (0.7)**b < 0.001**
239.7 (83.7)**a 217.2 (86.1)**b < 0.001**
6 (13%) 0 (0%)** 0.005*
1.
tage of this group).
Figure 3 The drainage blood loss rate (DBLR) at each time
point throughout 48-hour drainage recorded period, in all
three groups, showed a significant reduction in both TXA
groups compared to control group in the early period after
clamp release (the first 2-hour period in TXA-250 group and
the first 4-hour period in TXA-500 group (★ = p < 0.05). After
that, the mean DBLR in both TXA groups were decreased at a
slower rate than those in control group resulting in unexpected
significant greater in the mean DBLR in both TXA groups compared
to control group for several hours (★ = p < 0.05).
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tify any rare possible complications such as symptomatic
DVT or PE. Second, our study did not measure serum
TXA; however, the expected systemic absorption should




3 months 36.7 (8.2)**
6 months 25.4 (6.0)**
1 year 15.5 (6.6)**
p-value within group < 0.001**
Knee society knee score✝
3 months 121.7 (10.2)**
6 months 141.0 (11.5)**
1 year 148.9 (10.1)**





Congestive heart failure 0 (0%)
✝ = The values were presented as mean (standard deviation), ◆ = The values were p
group), **; p-value between time < 0.001, *; p < 0.05.
a = comparison between control and TXA-250 group with p < 0.05.
b = comparison between control and TXA-500 group with p < 0.05.negative pressure drainage system as demonstrated in our
result that the incidence of VTE was no statistical differ-
ence compared to control.
Our result demonstrated that intra-articular application
with low-dosage TXA, as 250 and 500 mg, was effective
for reducing postoperative blood loss in which comparable
with the result from previous studies that used TXA as a
single topical blood conservative agent (Table 4). Although
the DBL in both TXA groups significantly reduced only in
early period after clamp release compared with control
group (Figure 2), this result also comparable with the pre-
vious studies in Con-TKR [6,7]. However, two studies
[10,11] reported the significant reduction in the total DBL
between control group and IA-TXA group. This discrep-
ancy between our data and those studies might be ex-
plained by three reasons. First, our sample size in this
study was unable to detect a less-than 20% difference in
DBL between both TXA groups and control group. Sec-
ondly, the exact DBL in control group should be higher
than the presented value in Table 3 due to drain re-
clamping in 6 patients (13%) following our blood conser-
vative protocol. Finally, some surgical techniques in previ-
ous studies might enhance the efficacy of IA-TXA method
such as using high TXA dosage in minimally invasive sur-
gery TKR [11] and combined intraoperative hemostasis
with tourniquet release before wound closure [10].
Moreover, our data also demonstrated the ability to
reduce blood transfusion requirement as comparable
with Seo et al. [11] and Roy et al. [10] studies.in all three groups
TXA 250 mg TXA 500 mg p-value
(n = 45) (n = 45)
35.8 (7.6)** 35.5 (7.2)** 0.42
23.1 (6.5)** 23.5 (6.6)**
15.1 (6.2)** 14.5 (7.1)**
< 0.001** < 0.001**
121.1 (10.1)** 123.3 (9.1)** 0.91
141.2 (9.4)** 140.0 (8.9)**
151.2 (9.1)** 150.9 (9.3)**
< 0.001** < 0.001**
1 (2%) 0 (0%)*b 0.01
0 (0%)*a 0 (0%)*b 0.05
1 (2%) 2 (4%) 0.35
1 (2%) 0 (0%) 1.00
resented as number of patients having that condition (percentage of this






Prosthesis Technique used DBL THL CTBL BT
Early❖ Total
Wong (2010) [12] 1.5 & 3.0 IM Triathlon, Genesis II 5 min T.A., no drain n/a n/a Sig Sig NS
Maniar (2012) [7] 3.0 EM PFC Σ 5 min T.A., clamp drain♯
2 hr then fully open
Sig NS n/a Sig NS
Ishida (2011) [6] 2.0 IM Advance, Nexgen,
Scorpio, Vanguard, PFC Σ
IA, clamp drain 30 min
then gradually open
Sig NS Sig Sig NS
Seo (2012) [11] 1.5 EM Scorpio IA, with non-clamp drain n/a Sig Sig n/a Sig
Roy (2012) [10] 0.5 IM Scorpio IA, clamp drain 1 hr
then fully open
Sig Sig Sig n/a Sig
Sa-ngasoongsong
(2011) [9]
0.25 EM LCS, PFC Σ IA, clamp drain 2 hr
then fully open
Sig Sig Sig Sig Sig
This study 0.25, 0.5 IM Nexgen IA, clamp drain 2 hr
then fully open
Sig. N-S Sig. Sig. Sig
TXA; Tranexamic Acid, DBL; drainage blood loss, ❖; accumulated DBL in early period (6-24 hours after surgery).
THL; total hemoglobin loss, CTBL; calculated total blood loss, BT; blood transfusion.
IM; intramedullary femoral cutting guide, EM; extramedullary femoral cutting guide.
T.A; Topical application, IA; intra-articlar, min; minute, hr; hour, ♯; intra-articular drain.
n/a; not available, Sig; significant reduction compared with control group, NS; non-significant difference compared with control group.
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demonstrated the greater ability to reduce blood loss and
blood transfusion in TXA-500 group compared with
TXA-250 group (Figures 2 and 3). The 500-mg dosage sig-
nificantly reduced in both ADV and DBLR with higher de-
gree and also had a longer effect on DBLR compared to
the 250-mg dosage in the early period after drain opening.
This dose-dependent effect also demonstrated in Wong et al.
study [12] that used 5-minute topical application of 1.5-g
and 3.0-g TXA before wound closure without using drain.
Although DBL was unavailable to compare, the result on
THL and CTBL, between our study and Wong et al. study,
were comparable (as 27% and 34% reduction in mean CTBL
in TXA-250 and TXA-500 group respectively in this present
study compared with 20% and 25% reduction in mean CTBL
in 1.5-g and 3.0-g group in Wong et al. study). However, no
significant difference in blood transfusion requirement
between groups was found in Wong et al. [12] and
Maniar et al. [7] studies, which used 5-minute topical
application of 3.0-g TXA. The effect on blood transfusion
reduction between the low-dose IA-TXA application in
this present study and the high-dose TXA topical applica-
tion in previous studies [7,12] might be explained by the
“tissue contact time” or the time that TXA solution applied
on the surgical bed. Compared to those previous topical
TXA application studies, our study had a longer tissue
contact time (2 hours in our study versus 5 minutes in
Wong et al. and Maniar et al. study [7,12]). The prolonged
tissue contact time in our study, due to using clamping
drain technique, could enhance the effect of low-dose
IA-TXA resulting in more effective in controlling postop-
erative blood loss in early period, and better efficacy on
blood transfusion reduction.Our study also demonstrated an unexpected finding of
unique pattern of DBLR in both TXA groups that had de-
creased with a slower rate and resulted in a significant in-
crease in DBLR between 8 and 20 hours compared to
control group (Figure 3). This finding might be explained
by two possible reasons. First topical application of IA-
TXA with 2-hour drain clamping would result in a signifi-
cant greater thrombus formation than control group that
might produce more drainage volume from clot lysis. Sec-
ond, an abrupt reduction in the TXA amount in the surgi-
cal wound (from clamp release) might result in a relative
sudden activation of local fibrinolytic enzyme, such as
plasminogen and plasmin. Consequently, the suddenly ac-
tivated fibrinolysis would lead to a rapid clot lysis, or even
re-bleeding from small vessels in the surgical wound.Conclusion
In conclusion, the combined intra-articular application of
low-dose tranexamic acid, as 500 mg, with 2-hour clamp-
ing drain technique is effective for reducing postoperative
blood loss and transfusion requirement in conventional
total knee replacement without significant increase in
postoperative complication.
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